GlassScriptPhysician profile
John M Ventrudo
NPI 1639376999
$4,767.83
in general payments reported to CMS, 2019-2025
20 companies · $428 in 2025
The $428 reported for 2025 was more than what 76% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $304 · 2021: $379 · 2022: $607 · 2023: $1,029 · 2024: $1,575 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,444 · Travel and Lodging: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,444.29 |
| Travel and Lodging | $587.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,642.50 | 2019-2025 | Relistor |
| Pacira Pharmaceuticals Incorporated | $791.39 | 2024 | Iovera |
| Collegium Pharmaceutical, INC. | $536.95 | 2020-2025 | Xtampza |
| Valinor Pharma, LLC | $241.11 | 2023-2024 | Movantik |
| Biodelivery Sciences International, INC. | $230.61 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $223.90 | 2022-2023 | Ztlido |
| Relievant Medsystems, INC. | $200.81 | 2023 | Intracept |
| Daiichi Sankyo INC. | $152.91 | 2019 | |
| Revance Therapeutics, INC. | $134.30 | 2024 | Daxxify |
| Abbvie INC. | $126.42 | 2023-2025 | Botox |
| Forte Bio-Pharma LLC | $105.58 | 2024 | Prolate, Nalocet |
| Merz North America, INC. | $77.92 | 2023-2024 | Xeomin |
| Allergan, INC. | $74.35 | 2019-2022 | |
| Redhill Biopharma INC. | $60.24 | 2020 | |
| Biotronik Nro, INC. | $39.39 | 2025 | Prospera |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $39.02 | 2025 | Generator |
| Shionogi INC | $37.16 | 2019 | |
| Fidia Pharma USA INC. | $19.95 | 2025 | Triluron, Hymovis |
| Galderma Laboratories, L.P. | $17.47 | 2025 | |
| Boston Scientific Corporation | $15.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ventrudo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.